Monsalve 2017 Abstract MITOEAGLE Barcelona

Mitochondrial biogenesis in PMBC: potential biomarkers

Link: MITOEAGLE

Fabregat-Andres O, Ridocci-Soriano F, Berenguer-Jofresa A, Corbi-Pascual M, Valle-Munoz A, Barrabes JA, Estornell-Erill J, M, Monsalve M (2017)

Event: MITOEAGLE Barcelona 2017

Peroxisome proliferator activated receptor g co-activator 1a (PGC-1a) is a master on antioxidant systems. It is induced by ischemia and reperfusion (IR) and has been shown to prevent cardiac remodeling in mice. PGC-1a can be detected in blood samples of ST-segment elevation acute myocardial infarction (STEMI) patients. This study tested the predictive value of PGC-1a for cardiac healing and adverse ventricular remodeling (AVR) after STEMI.

We prospectively studied 31 patients with a first anterior STEMI successfully reperfused. We analyzed PGC-1a mRNA in blood samples on admission and 72 h later, and tested its correlation with the extent of initial myocardial damage and cardiac volume and function at 6 months. Myocardial edema and necrosis were assessed during the first week by cardiac magnetic resonance (CMR). A second CMR examination was performed at 6 months to evaluate scar burden and AVR, defined as an increase over 10% in left ventricular end-diastolic volume (LVEDV).

PGC-1a induction is associated with larger edemas and higher risk of AVR. Patients with high basal PGC-1a levels have larger areas of initial salvaged myocardium (SM) and SM at 6 months. In the absence of microvascular obstruction (MVO) and with high basal PGC-1a, the risk of AVR is lower than in the presence of MVO with low basal PGC-1a.

Baseline expression and lack of induction of PGC-1a are associated with a reduced incidence of AVR after STEMI.

Labels: MiParea: mt-Biogenesis;mt-density 

Tissue;cell: Blood cells 

Event: A4  PMBCs 

Affiliations

Consorcio Hospital General Univ Valencia, Inst Investigaciones Biomédicas “Alberto Sols” (CSIC), Madrid; Spain.